Allergy Unit, Verona University Hospital, Piazzale Aristide Stefani 1, 37126 Verona, Italy.
Expert Rev Clin Immunol. 2013 Oct;9(10):937-47. doi: 10.1586/1744666X.2013.837262. Epub 2013 Oct 7.
Over the last 20 years, studies and clinical trials have demonstrated efficacy, safety and cost-effectiveness of sublingual immunotherapy (SLIT) for respiratory allergic diseases. Nevertheless, it seems to be mostly used as a second-line therapeutic option, and adherence to treatment is not always optimal. Selective literature research was done in Medline and PubMed, including guidelines, position papers and Cochrane meta-analyses concerning SLIT in adult patients. The most recent reviews confirm SLIT as viable and efficacious treatment especially for allergic rhinitis, even if the optimal dosage, duration, schedule are not clearly established for most of the products. Despite an optimal safety profile, tolerability and patient-reported outcomes concerning SLIT have received poor attention until now. Recently, new tools have been specifically developed in order to investigate these aspects. Regular assessment of tolerability profile and SLIT-related patient-reported outcomes will allow balancing efficacy with tolerability and all the other patient-related variables that may affect treatment effectiveness beyond its efficacy.
在过去的 20 年中，研究和临床试验已经证明了舌下免疫疗法（SLIT）治疗呼吸道过敏性疾病的疗效、安全性和成本效益。然而，它似乎主要被用作二线治疗选择，而且患者对治疗的依从性并不总是最佳的。在 Medline 和 PubMed 中进行了选择性文献研究，包括针对成年患者 SLIT 的指南、立场文件和 Cochrane 荟萃分析。最近的综述证实，SLIT 是一种可行且有效的治疗方法，特别是对于过敏性鼻炎，尽管大多数产品的最佳剂量、持续时间和方案尚未明确确定。尽管 SLIT 具有最佳的安全性、耐受性和患者报告的结局，但迄今为止，人们对其关注甚少。最近，专门开发了新的工具来研究这些方面。定期评估耐受性和与 SLIT 相关的患者报告的结局将有助于平衡疗效与耐受性以及所有其他可能影响治疗效果的患者相关变量，而不仅仅是其疗效。
